Urology Associates

Recent papers from Urology Associates

1. Cardiovascular Risk Triage Schema for Patients With Prostate Cancer Treated With Hormone TherapyJCO Oncology Practice · 2026
2. Urodynamic Outcomes Following Photovaporization of the Prostate for Benign Prostatic Hyperplasia: A Retrospective Pressure-Flow AnalysisUro · 2026
3. Durable Responses and Cystectomy Avoidance with IL-15 Receptor Agonist NAI plus BCG In BCG-Unresponsive NMIBC with Carcinoma In Situ +/- Papillary DiseaseThe Journal of Urology · 2026
4. Invisible symptoms in multiple sclerosis and their impact on social role participation: A multidimensional analysisMultiple Sclerosis Journal · 2026
5. Suspected Autoimmune Encephalitis in Hospitalized Adults: Diagnostic Yield and Predictors (P9-1.007)Neurology · 2026
6. (667) Residual Bacterial Presence Cultured During Revision Penile Implant Surgery for Any Reason Has Drastically Reduced From 67.6% to 2.9% Over the Past 40 Years as Surgeons and Manufacturers Have Altered the Disciplines of Infection ControlThe Journal of Sexual Medicine · 2026
7. Assessing responses to UGN-102 across EORTC recurrence score groups in patients with recurrent low-grade intermediate-risk NMIBC (ENVISION trial).Journal of Clinical Oncology · 2026
8. Analysis of PLEKHS1 promoter mutation in preoperative thyroid nodule samplesCancer Cytopathology · 2026
9. Non-Invasive Urine Test Predicts Grade Group Upgrading in Patients on Active Surveillance for Prostate Cancer: Multisite Validation and Comparison with MRI.2026
10. Estimate renal cell carcinoma recurrence rates using electronic health recordsESMO Real World Data and Digital Oncology · 2026
11. Consensus Recommendations for Disease- and Treatment-Related Fatigue in Patients With Advanced Prostate Cancer: A Modified Delphi PanelJournal of the National Comprehensive Cancer Network · 2026
12. UGN-102 for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer: 24-Month Duration of Response Results From the Phase 3 ENVISION TrialThe Journal of Urology · 2026
13. ADVANCED-2: Interim efficacy and safety data in BCG-unresponsive participants with high-grade non-muscle invasive bladder cancer.Journal of Clinical Oncology · 2026
14. A phase 2 multicenter, open-label study evaluating the efficacy and safety of dabogratinib (TYRA-300) in participants with FGFR3-altered low-grade, intermediate risk non-muscle invasive bladder cancer (SURF302).Journal of Clinical Oncology · 2026
15. Interim safety and tolerability of TARA-002 in patients with BCG-naïve and unresponsive high-grade non-muscle invasive bladder cancer in ADVANCED-2.Journal of Clinical Oncology · 2026
16. The effect of elbow posture on biceps function at the shoulder in brachial plexus birth injuries: A computational sensitivity analysisClinical Biomechanics · 2026
17. Comparative Effectiveness and Risk of Severe Infection in Adult Patients With MS Treated With Diroximel Fumarate Versus Anti-CD20 Monoclonal Antibodies: A Real-World Claims AnalysisAdvances in Therapy · 2026
18. Preoperative Detection of Dual TERT Promoter Mutations in Thyroid Cancer: A Case SeriesDiagnostic Cytopathology · 2026
19. The Impact of Diet, Exercise and Obstructive Sleep Apnea on Atherogenic Erectile Dysfunction: An Expert ReviewAmerican Journal of Lifestyle Medicine · 2026
20. Does addition of multiparametric MRI to PSMA PET/CT improve diagnostic accuracy for biochemical recurrence after radical prostatectomy?BJU International · 2026